Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2

American Journal of Pathology

Volumn 166, Issue 2, 2005, Pages 575-584

  Müller Decker, Karin ^a   Berger, Irina ^b   Ackermann, Karin ^a   Ehemann, Volker ^b   Zoubova, Svetlana ^a   Aulmann, Sebastian ^b   Pyerin, Walter ^a   Fürstenberger, Gerhard ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLOOXYGENASE 2; KERATIN; KERATIN 5; MESSENGER RNA; PROSTAGLANDIN E2; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BREAST DYSPLASIA; BREAST EPITHELIUM; BREAST FIBROSIS; BREAST HYPERPLASIA; BREAST TUMOR; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CYSTIC DUCT; FEMALE; HORMONE DEPENDENCE; HUMAN; HUMAN TISSUE; LACTATION; MAMMARY GLAND; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; MYOEPITHELIUM CELL; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION;

EID: 13244273816     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62279-1     Document Type: Article

References (49)

1. Page JR, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, O'Hare JO: Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA 1999, 96:12589-12594
2. Ma X-J, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC: Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003, 100:5974-5979
3. Foschini MP, Eusebi V: Carcinomas of the breast showing myoepithelial cell differentiation. A review of the literature. Virchows Arch 1998, 432:303-310
4. Lakhani SR, O'Hare MJ: The mammary myoepithelial cell - Cinderella or ugly sister? Breast Cancer Res 2001, 3:1-4
5. Lundin C, Mertens F: Cytogenetics of benign breast lesions. Breast Cancer Res Treatment 1998, 51:1-15
6. Xiao G, Liu YE, Gentz R, Sang QA, Ni J, Goldberg ID, Shi YE: Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells. Proc Natl Acad Sci USA 1999, 96:3700-3705
7. Brown PH, Lippman SM: Chemoprevention of breast cancer. Breast Cancer Res 2000, 62:1-17
8. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348:2431-2442
9. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182
10. Turini ME, DuBois RN: Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002, 53:35-57
11. Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ: Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001, 8:97-114
12. Singh-Ranger G, Mokbel K: Role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol 2002, 28:729-737
13. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002, 62:632-635
14. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002, 62:1676-1681
15. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ: Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. J Biol Chem 2002, 277:18649-18657
16. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AMC, Dannenberg AJ: Celecoxib, a selective COX-2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002, 62:5405-5407
17. Liu CH, Chang SH, Narko K, Trifan OC, Wu M-T, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001, 276:18563-18569
18. Chang S-H, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 2004, 101:591-596
19. Neufang G, Fürstenberger G, Heidt M, Marks F, Müller-Decker K: Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci USA 2001, 98:7629-7634
20. Müller-Decker K, Kopp-Schneider A, Seibert K, Marks F, Fürstenberger G: Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinog 1998, 23:36-44
21. Müller-Decker K, Reinerth G, Krieg P, Zimmermann R, Heise H, Bayerl C, Marks F, Fürstenberger G: Prostaglandin H synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999, 82:648-656
22. Müller-Decker K, Scholz K, Marks F, Fürstenberger G: Differential expression of prostaglandin H synthase isozyme expression during multistage carcinogenesis in mouse epidermis. Mol Carcinog 1995, 12:31-41
23. Müller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Fürstenberger G: Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 2002, 99:12483-12488
24. Ehemann V, Sykora J, Vera-Delgado J, Lange Adelheid, Otto HF: Flow cytometric detection of spontaneous apoptosis in human breast cancer using the TUNEL-technique. Cancer Lett 2003, 194:125-131
25. Dupont WD, Page MD: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985, 312:146-151
26. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K: 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000, 43:775-777
27. Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57:4987-4991
28. Simpson ER, Mahendroo MS, Means GD, Kilgroe MW, Hinselwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun S: Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994, 15:342-355
29. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trazaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809
30. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R: Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 60:4705-4708
31. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R: Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002, 62:3395-3401
32. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000, 105:1589-1594
33. Lakhani SR: The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999, 187:272-278
34. Yue W, Santen RJ, Wang JP, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL: Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003, 86:477-486
35. Liehr JG: Is estradiol a genotoxic mutagenic carcinogen? Endocrine Rev 2000, 21:40-54
36. Liehr JG: Role of DNA adducts in hormonal carcinogenesis. Reg Toxicol Pharmacol 2000, 32:276-282
37. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:493-501
38. Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79:1193-1226
39. Purohit A, Reed, MJ: Regulation of estrogen synthesis in postmenopausal women. Steroids 2002, 67:979-983
40. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996, 137:5739-5742
41. Davies G, Martin L-A, Sacks N, Dowsett M: Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 2002, 13:669-678
42. Richards JA, Brueggemeier RW: Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab 2003, 88:2810-2816
43. Johnston SRD, Dowsett M: Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003, 3:821-831
44. Shaaban AM, Sloane JP, West CR, Foster CS: Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor α and Ki67 expression. Am J Pathol 2002, 160:597-604
45. Tekmal RR, Ramachandra N, Gubba S, Durgam VR, Mantione J, Toda K, Shizuta Y, Dillehay DL: Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 1996, 56:3180-3185
46. Donegan WL: Cancer of the Breast, ed 5. Edited by Donegan WL, Spratt JS. St. Louis, Saunders, 2002, pp 67-110
47. Selim AA, Wells CA: Immunohistochemical localization of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. J Clin Pathol 1999, 52:838-841
48. Tan-Chiu E, Wang J, Costantino JP, Paik S, Butch C, Wickerham DL, Fisher B, Wolmark N: Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003, 95:302-307
49. Minami Y, Ohuchi N, Taeda Y, Takano A, Fukao A, Satomi S, Hisamichi S: Risk of breast cancer in Japanese women with benign breast disease. Jpn J Cancer Res 1999, 90:600-606